Brand-name drug
Ingrezza price, strengths & recalls
Brand of valbenazine (generic)
Pharmacies pay $8,117.59 for 30 capsules of Ingrezza 40 mg capsule this week, and from $8,117.59 to $8,754.46 across its 3 priced strengths and forms. Its official label last changed on April 22, 2026.
Brand- Fair cash price
- $9,345.73
- Strengths
- 3
- Makers
- 1
- Updated
- Nov 11
Ingrezza price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 40 mg capsule Brand | $270.59 | $8,117.59 / 30 capsules |
| 60 mg capsule Brand | $291.82 | $8,754.46 / 30 capsules |
| 80 mg capsule Brand | $291.82 | $8,754.46 / 30 capsules |
The lowest cost per capsule is 40 mg capsule at $270.59. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Ingrezza vs generic valbenazine
There is no generic version of Ingrezza on the market yet. Its last listed patent or exclusivity runs to August 10, 2040 - generics often follow, though court cases and settlements can move the date either way.
GenericValbenazine pricesSupply status: shortages & recalls
What people paid for Ingrezza
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use INGREZZA or INGREZZA SPRINKLE safely and effectively. See full prescribing information for INGREZZA. INGREZZA® (valbenazine) capsules, for oral useINGREZZA® SPRINKLE (valbenazine) capsules, for oral useInitial U.S. Approval: 2017
WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON'S DISEASE
VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.
Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease [see Warnings and Precautions (5.1)].
WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON'S DISEASE
See full prescribing information for complete boxed warning.
• Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease (5.1)
• Balance risks of depression, and suicidal ideation and behavior with the clinical need for treatment of chorea when considering the use of INGREZZA or INGREZZA SPRINKLE (5.1)
• Monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior (5.1)
• Inform patients, caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician (5.1)
• Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation (5.1)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA209241 · Neurocrine
- First approved
- April 11, 2017 (9 years ago)
- Latest approved change
- October 23, 2026
- Approved label
- PDF, Oct 27, 2026
- Generic makers
- None on the market
- Last patent listed
- August 10, 2040
- Exclusivity ends
- August 18, 2030
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Ingrezza questions
How much does ingrezza cost without insurance?
Pharmacies pay about $8,117.59 for 30 capsules of ingrezza 40 mg capsule ($270.59 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $9,345.73. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Ingrezza?
Yes: valbenazine. Compare valbenazine prices.
Is ingrezza in shortage?
No shortage is reported for ingrezza right now. We check the national shortage list every day.
Has ingrezza been recalled?
No recalls are on record for ingrezza.
When did the ingrezza label last change?
The official label was last updated on April 22, 2026 (version 34). See what changed.
Talk about ingrezza
No comments yet. Questions, tips, what worked for you - start the conversation.